Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Gynecologic 6Genitourinary 4Gastrointestinal 4Thoracic 3Sarcoma 2Breast 2Myeloid 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 1

Interventions

Blood Specimen Collection 22Surveys and Questionnaires 19Nivolumab 14Ipilimumab 12pembrolizumab 11Gene Expression Profiling 11Biopsy 10trametinib 9dabrafenib 8Flow Cytometry 8Specimen Handling 7Polymerase Chain Reaction 7Tomography, Optical Coherence 6Therapeutics 6Immunohistochemistry 6Imiquimod 6Amplified Fragment Length Polymorphism Analysis 6Watchful Waiting 5Psychiatric Rehabilitation 5Immunotherapy 5Data Collection 53-ingenyl angelate 5Mohs Surgery 4Microarray Analysis 4Interviews as Topic 4Immunoenzyme Techniques 4Drug Therapy 4Dermoscopy 4sonidegib 3encorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × DNA Methylation × Dermatologic × Clear all
NCT01209299 2017-05-17

Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

Eastern Cooperative Oncology Group

Completed
80 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡